BIOMAT Database Logo BIOMAT Database Logo

Transdermal therapeutic fentanyl-system (TTS-F). 2004

Kyriaki Mystakidou, and Emmanuela Katsouda, and Eleni Tsilika, and Efi Parpa, and Lambros Vlahos
Department of Radiology, University of Athens, School of Medicine, Korinthias 27, Athens 115 26, Greece. mistakidou@yahoo.com

Fentanyl, a surgical analgesic and general anaesthetic, is a lipophilic short-acting synthetic opioid, having a selective potent effect on mu receptors. The transdermal therapeutic fentanyl-system (TTS-F) allows for a continued and sustained titratable amount of fentanyl to be delivered without the inconvenience of the typical 24-h administration of other analgesics. Although incidences of respiratory depression led to TTS-F being contraindicated for postoperative analgesia, it is currently undergoing Phase III trials for nociceptive, neuropathic and chronic moderate to severe pain in a variety of settings. It demonstrates a slow pharmacokinetic profile and incidences of breakthrough pain may still require rapid analgesia, for which intravenous and bolus administration of rapid acting opioids remain 'gold standard' However, TTS-F is finding uses for chronic pain of cancer origin where it offers a solution for step 3-pain (WHO) management on the WHO analgesic ladder. More recent data indicates that TTS-F is not only effective for neuropathic but also nociceptive non-cancer and cancer pain alike. This review presents an overview of the synthesis, delivery, pharmacokinetics, toxicity and clinical pharmacology of the transdermal delivery of fentanyl.

UI MeSH Term Description Entries
D010146 Pain An unpleasant sensation induced by noxious stimuli which are detected by NERVE ENDINGS of NOCICEPTIVE NEURONS. Suffering, Physical,Ache,Pain, Burning,Pain, Crushing,Pain, Migratory,Pain, Radiating,Pain, Splitting,Aches,Burning Pain,Burning Pains,Crushing Pain,Crushing Pains,Migratory Pain,Migratory Pains,Pains, Burning,Pains, Crushing,Pains, Migratory,Pains, Radiating,Pains, Splitting,Physical Suffering,Physical Sufferings,Radiating Pain,Radiating Pains,Splitting Pain,Splitting Pains,Sufferings, Physical
D002908 Chronic Disease Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2). Chronic Condition,Chronic Illness,Chronically Ill,Chronic Conditions,Chronic Diseases,Chronic Illnesses,Condition, Chronic,Disease, Chronic,Illness, Chronic
D005283 Fentanyl A potent narcotic analgesic, abuse of which leads to habituation or addiction. It is primarily a mu-opioid agonist. Fentanyl is also used as an adjunct to general anesthetics, and as an anesthetic for induction and maintenance. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1078) Phentanyl,Duragesic,Durogesic,Fentanest,Fentanyl Citrate,Fentora,R-4263,Sublimaze,Transmucosal Oral Fentanyl Citrate,R 4263,R4263
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000279 Administration, Cutaneous The application of suitable drug dosage forms to the skin for either local or systemic effects. Cutaneous Drug Administration,Dermal Drug Administration,Drug Administration, Dermal,Percutaneous Administration,Skin Drug Administration,Transcutaneous Administration,Transdermal Administration,Administration, Dermal,Administration, Transcutaneous,Administration, Transdermal,Cutaneous Administration,Cutaneous Administration, Drug,Dermal Administration,Drug Administration, Cutaneous,Skin Administration, Drug,Administration, Cutaneous Drug,Administration, Dermal Drug,Administration, Percutaneous,Administrations, Cutaneous,Administrations, Cutaneous Drug,Administrations, Dermal,Administrations, Dermal Drug,Administrations, Percutaneous,Administrations, Transcutaneous,Administrations, Transdermal,Cutaneous Administrations,Cutaneous Administrations, Drug,Cutaneous Drug Administrations,Dermal Administrations,Dermal Drug Administrations,Drug Administrations, Cutaneous,Drug Administrations, Dermal,Drug Skin Administrations,Percutaneous Administrations,Skin Administrations, Drug,Skin Drug Administrations,Transcutaneous Administrations,Transdermal Administrations
D000701 Analgesics, Opioid Compounds with activity like OPIATE ALKALOIDS, acting at OPIOID RECEPTORS. Properties include induction of ANALGESIA or NARCOSIS. Opioid,Opioid Analgesic,Opioid Analgesics,Opioids,Full Opioid Agonists,Opioid Full Agonists,Opioid Mixed Agonist-Antagonists,Opioid Partial Agonists,Partial Opioid Agonists,Agonist-Antagonists, Opioid Mixed,Agonists, Full Opioid,Agonists, Opioid Full,Agonists, Opioid Partial,Agonists, Partial Opioid,Analgesic, Opioid,Full Agonists, Opioid,Mixed Agonist-Antagonists, Opioid,Opioid Agonists, Full,Opioid Agonists, Partial,Opioid Mixed Agonist Antagonists,Partial Agonists, Opioid
D017326 Clinical Trials, Phase III as Topic Works about comparative studies to verify the effectiveness of diagnostic, therapeutic, or prophylactic drugs, devices, or techniques determined in phase II studies. During these trials, patients are monitored closely by physicians to identify any adverse reactions from long-term use. These studies are performed on groups of patients large enough to identify clinically significant responses and usually last about three years. This concept includes phase III studies conducted in both the U.S. and in other countries. Clinical Trials, Phase 3 as Topic,Drug Evaluation, FDA Phase 3 as Topic,Drug Evaluation, FDA Phase III as Topic,Evaluation Studies, FDA Phase 3 as Topic,Evaluation Studies, FDA Phase III as Topic

Related Publications

Kyriaki Mystakidou, and Emmanuela Katsouda, and Eleni Tsilika, and Efi Parpa, and Lambros Vlahos
Withdrawal symptoms during therapy with transdermal fentanyl (fentanyl TTS)?
January 1994, Journal of pain and symptom management,
Kyriaki Mystakidou, and Emmanuela Katsouda, and Eleni Tsilika, and Efi Parpa, and Lambros Vlahos
[Transdermal therapeutic systems (TTS)].
December 1998, Medizinische Monatsschrift fur Pharmazeuten,
Kyriaki Mystakidou, and Emmanuela Katsouda, and Eleni Tsilika, and Efi Parpa, and Lambros Vlahos
[Transdermal therapeutic systems (TTS)].
December 1988, Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete,
Kyriaki Mystakidou, and Emmanuela Katsouda, and Eleni Tsilika, and Efi Parpa, and Lambros Vlahos
[Tumor pain. Fentanyl TTS: a transdermal system for tumor pain therapy].
October 1995, Deutsche medizinische Wochenschrift (1946),
Kyriaki Mystakidou, and Emmanuela Katsouda, and Eleni Tsilika, and Efi Parpa, and Lambros Vlahos
[Treatment of chronic pain--use of transdermal fentanyl (Durogesic TTS)].
January 2002, Reumatizam,
Kyriaki Mystakidou, and Emmanuela Katsouda, and Eleni Tsilika, and Efi Parpa, and Lambros Vlahos
TTS-fentanyl.
January 1989, Cancer investigation,
Kyriaki Mystakidou, and Emmanuela Katsouda, and Eleni Tsilika, and Efi Parpa, and Lambros Vlahos
Studies of the bioavailability of nitroglycerin from a transdermal therapeutic system (Nitroderm TTS).
January 1984, European journal of clinical pharmacology,
Kyriaki Mystakidou, and Emmanuela Katsouda, and Eleni Tsilika, and Efi Parpa, and Lambros Vlahos
Alghedon Fentanyl Transdermal System.
April 2017, Minerva medica,
Kyriaki Mystakidou, and Emmanuela Katsouda, and Eleni Tsilika, and Efi Parpa, and Lambros Vlahos
Fentanyl Iontophoretic Transdermal System.
January 2016, Hospital pharmacy,
Kyriaki Mystakidou, and Emmanuela Katsouda, and Eleni Tsilika, and Efi Parpa, and Lambros Vlahos
[Transdermal System-Buprenorphine and Fentanyl].
November 2015, Masui. The Japanese journal of anesthesiology,
Copied contents to your clipboard!